Asset Details
Do you wish to reserve the book?
Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
Do you wish to request the book?
Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
2020
Overview
Background
The pharmacokinetics of vancomycin, a drug used for the treatment of methicillin-resistant
Staphylococcus aureus
(MRSA), varies between paediatric and adult patients.
Objective
The objective of this study was to assess the pharmacokinetics of vancomycin in preterm neonates and determine the optimum dose regimen.
Methods
This was a randomised double-blind study of preterm neonates admitted to neonatal intensive care units. They all received vancomycin 15 mg/kg every 12 h. Blood was sampled just before administration of the third, sixth and ninth vancomycin dose. Pharmacokinetic parameters were estimated using a Bayesian approach implemented in Monolix 2018R2 software. Covariates assessed included postmenstrual age, current weight, creatinine clearance, albumin, gestational age, body surface area and current age. We used Monte Carlo simulations for dose regimen optimisation targeting area under the concentration–time curve up to 24 h (AUC
0–24h
) of ≥ 400 mg × h/L.
Results
In total, 19 preterm neonates were enrolled in the study with a median age of 14 (3–58) days. A one-compartment model with linear elimination best described the pharmacokinetics of vancomycin. Volume of distribution and clearance was 0.88 L and 0.1 L/h, respectively, for a typical neonate weighing 1.48 kg. Simulation of the current dose regimen showed that 27.5% of the neonates would achieve the target AUC
0–24h
of ≥ 400 mg × h/L, and 70.7% of the neonates would achieve it with 12 mg/kg every 8 h.
Conclusion
The majority of the neonates were under dosed. Vancomycin 12 mg/kg should be administered every 8 h over 1 h infusion to improve the likelihood of achieving the AUC
0–24h
target of ≥ 400 mg × h/L. This target is considered optimal for MRSA infections, where the vancomycin minimum inhibitory concentration is ≤ 1 µg/mL.
Publisher
Springer International Publishing,Springer Nature B.V,Adis, Springer Healthcare
Subject
Anti-Bacterial Agents - administration & dosage
/ Anti-Bacterial Agents - blood
/ Anti-Bacterial Agents - pharmacokinetics
/ Dose-Response Relationship, Drug
/ Humans
/ Infant, Premature, Diseases - blood
/ Infant, Premature, Diseases - drug therapy
/ Intensive Care Units, Neonatal
/ Medicine
/ Methicillin-Resistant Staphylococcus aureus - drug effects
/ Original
/ Plasma
/ Sepsis
/ Staphylococcal Infections - blood
/ Staphylococcal Infections - drug therapy
